EGF-Like-Domain, Multiple 7 (EGFL7) Kits ELISA

EGFL7 encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. De plus, nous expédions EGFL7 Anticorps (74) et EGFL7 Protéines (13) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
EGFL7 353156 Q9QXT5
EGFL7 51162 Q9UHF1
EGFL7 245963 Q6AZ60
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top EGFL7 Kits ELISA sur anticorps-enligne.fr

Showing 4 out of 21 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Livraison Prix Détails
Humain 13.1 pg/mL 31.25 pg/mL - 2000 pg/mL 96 Tests 13 to 16 Days
$810.53
Détails
Souris 0.062 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests 13 to 16 Days
$833.68
Détails
Rat 1.56 ng/mL n/a   96 Tests 15 to 18 Days
$910.56
Détails
Humain 14.8 pg/mL 31.2 pg/mL - 2000 pg/mL   96 Tests 15 to 17 Days
$1,055.03
Détails

EGFL7 Kits ELISA mieux référencés

  1. Human EGFL7 Kit ELISA pour Sandwich ELISA - ABIN1874436 : Hansen, Andersen, Olsen, Sørensen, Jakobsen: Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. dans Scientific reports 2017 (PubMed)

Plus Kits ELISA pour EGFL7 partenaires d'interaction

Xenopus laevis EGF-Like-Domain, Multiple 7 (EGFL7) interaction partners

  1. we demonstrate for the first time the mechanisms by which lumens are generated within the major vessels in Xenopus and implicate EGFL7 in modulating cell shape and cell-cell junctions to drive proper lumen morphogenesis.

  2. CASZ1/Egfl7/RhoA pathway is necessary for promoting endothelial cell behaviors associated with proper vascular assembly.

Zebrafish EGF-Like-Domain, Multiple 7 (EGFL7) interaction partners

  1. Under up-regulation of TIE2-R849W, egfl7 could be considered a potential reason for venous defects. Moreover, the wnt pathway may perform an important role as a key trigger for head multi-malformations.

  2. loss of Egfl7 function in zebrafish embryos specifically blocks vascular tubulogenesis

  3. These data suggest that Egfl7 provides endothelial cells (EC) with a cue for their extension into the vascular area and in establishing EC cell polarity.

  4. EGFL7 provides a proper microenvironment for endothelial cell migration, thereby enabling accurate patterning.

Mouse (Murine) EGF-Like-Domain, Multiple 7 (EGFL7) interaction partners

  1. Loss of EGFL7 causes an accumulation of activated neural stem cells, which display enhanced activity and re-entry into the cell cycle.

  2. EGFL7 reduces CNS inflammation in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

  3. Egfl7 is crucial for placental vascularization and embryonic growth.

  4. the angiogenic factor Egfl7 activates the Flt3/Flt3 ligand pathway and is a key molecular driver enforcing thymus progenitor generation and thereby directly links endothelial cell biology to the production of T cell-based adaptive immunity

  5. EGFL7 is required for VEGF upregulation of the Akt/Erk (1/2) pathway during angiogenesis.

  6. EGFL7 enhances EGFR-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.

  7. Egfl7 could be a HIF-1alpha responsive gene regulated by oxygen tension.

  8. Using the BPH/5 model of pre-eclampsia (PE), we show that the downregulation of Egfl7 in compromised placentas occurs prior to the onset of characteristic maternal signs of PE.

  9. egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries.

  10. EGFL7 is expressed in the bone microenvironment and has a role in promoting endothelial cell migration and tube-like structure formation through integrin-mediated pathways.

  11. Expression of Egfl7 in breast and lung carcinoma cells accelerates tumor growth and metastasis in immunocompetent mice but not in immunodeficient mice.

  12. Overexpression of endothelial Egfl7 is associated with impaired angiogenesis and altered Notch signaling

  13. the expression of the VE-statin/egfl7 gene in endothelial cells and the specific importance of ETS and GATA factors

  14. is the first identified inhibitor of mural cell migration specifically produced by endothelial cells.

  15. regulator that controls a specific and important step in vasculogenesis

  16. EGFL7 protein is localized to the endoplasmic reticulum and Golgi apparatus, suggesting that the protein is targeted for secretion

  17. The recombinant protein is pure as assessed by SDS-PAGE, immunoblot and mass spectrometry, and is biologically active as a repressor of human aortic smooth muscle cell migration induced by platelet-derived growth factor-BB.

  18. EGFL7 defines the optimal path of endothelial cells movement by assuring the correct positioning of each EC in a nascent sprout.

  19. EGFL7 provides a proper microenvironment for endothelial cell migration, thereby enabling accurate patterning.

  20. VE-statin/egfl7 produced by endothelial cells binds to the catalytic domains of enzymes of the LOX family in the vascular wall, thereby preventing the crosslink of tropoelastin molecules into mature elastin polymers and regulating vascular elastogenesis.

Human EGF-Like-Domain, Multiple 7 (EGFL7) interaction partners

  1. increased release of placenta-derived EGFL7 and increased circulating levels of EGFL7 are associated with the clinical manifestation of preeclampsia.

  2. EGFL7 expression promoted glioma growth in experimental glioma models in vivo and stimulated tumor vascularization. Mechanistically, this was mediated by an upregulation of integrin alpha5beta1 on the cellular surface of endothelial cells, which enhanced fibronectin-induced angiogenic sprouting.

  3. Tissues from patients with serous and non-serous EOC showed significantly higher promoter methylation of EGFL7 and RASSF1 compared to benign cases.

  4. Data show that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was much higher than that of non-invasive GHPA.

  5. EGFL7 was found to be a potential predictor for HCC survival and metastasis state.

  6. Levels of both EGFL7 mRNA and EGFL7 protein are increased in blasts of patients with acute myeloid leukemia (AML) compared with normal bone marrow cells. High EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) and younger (age <60 y) patients with cytogenetically normal AML.

  7. In conclusion, miR-126 could inhibit tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

  8. This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer

  9. Oncogenic activation of EGFRwt in GBM is likely maintained by a continuous EGFL7 autocrine flow line.

  10. our results indicated epidermal growth factor-like domain multiple 7 protein participates in growth hormone-secreting pituitary adenoma proliferation and invasion regulation via Notch2/DLL3 signaling pathway. These findings raised the possibility that epidermal growth factor-like domain multiple 7 protein might serve as a useful biomarker to assess growth hormone-secreting pituitary adenoma invasion and prognosis

  11. Egfl7 is thus an endogenous and constitutive repressor of blood vessel endothelial cell activation in normal and inflammatory conditions and participates in a loop of regulation of activation of these cells by pro-inflammatory cytokines.

  12. Up-regulated MALAT1 promoted the invasion and metastasis of GC, and the increase of EGFL7 expression was a potential mechanism via altering its H3 histone acetylation level

  13. These findings suggest that the stimulating effect of EGFL7-ESCs on fibroblast proliferation and migration may provide a useful strategy for wound healing.

  14. A gene expression study was conducted to investigate the levels of Egfl7 and miRNA126-5p in human carotid artery atherosclerotic plaques

  15. By regulating endothelial cell adhesion, EGFL7 plays a key role in the regulation of glioma angiogenesis.

  16. The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase.

  17. EGFR mutational analysis is useful in the diagnosis of non-small-cell-lung cancer.

  18. The aim of the present descriptive study was to analyse the intra-tumoural expressions of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126 (miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer.

  19. EGFL7, OPN, and PGE2 may have a role in recurrence and metastasis of hepatocellular carcinoma

  20. High EGFL7 expression promotes migration and Epithelial-Mesenchymal Transition in pancreatic Cancer.

EGFL7 profil antigène

Antigen Summary

This gene encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. The encoded protein may play a role in regulating vasculogenesis. This protein may be involved in the growth and proliferation of tumor cells. Alternate splicing results in multiple transcript variants.

Gene names and symbols associated with EGFL7

  • EGF like domain multiple 7 S homeolog (egfl7.S) anticorps
  • EGF like domain multiple 7 (EGFL7) anticorps
  • EGF-like-domain, multiple 7 (egfl7) anticorps
  • EGF like domain multiple 7 (egfl7) anticorps
  • EGF-like domain 7 (Egfl7) anticorps
  • EGF-like-domain, multiple 7 (Egfl7) anticorps
  • EGFL7 anticorps
  • MGC53105 anticorps
  • MGC147423 anticorps
  • NEU1 anticorps
  • RP11-251M1.2 anticorps
  • VE-STATIN anticorps
  • xegfl7 anticorps
  • zgc:136669 anticorps
  • zgc:152804 anticorps
  • ZNEU1 anticorps

Protein level used designations for EGFL7

EGF-like-domain, multiple 7 , epidermal growth factor-like protein 7 , rp11-251m1.2 , EGF-like protein 7 , NEU1 protein , NOTCH4-like protein , multiple EGF-like domains protein 7 , multiple epidermal growth factor-like domains protein 7 , vascular endothelial statin , vascular endothelial-statin , EGF-like domain 7 , EGF-like domain-containing protein 7 , Estrogen-regulated protein CBL20 20.4kD , Estrogen-regulated protein CBL20, 20.4kD , multiple EGF-like domain protein 7 , multiple epidermal growth factor-like domain protein 7

GENE ID SPECIES
379835 Xenopus laevis
417137 Gallus gallus
464868 Pan troglodytes
491250 Canis lupus familiaris
613671 Bos taurus
678640 Danio rerio
780371 Xenopus (Silurana) tropicalis
100226311 Taeniopygia guttata
353156 Mus musculus
51162 Homo sapiens
245963 Rattus norvegicus
Fournisseurs de qualité sélectionnés pour EGFL7 (EGFL7) Kits ELISA
Avez-vous cherché autre chose?